Risperidone or Aripiprazole for Aggression in Autism
For treating aggression and angry outbursts in individuals with autism, risperidone (0.5-3.5 mg/day) or aripiprazole (5-15 mg/day) are the most effective medications, with risperidone showing a 69% positive response rate versus 12% for placebo, and aripiprazole demonstrating 56% response versus 35% for placebo. These are the only two FDA-approved medications specifically for irritability (which encompasses aggression and tantrums) in autism spectrum disorder 1.
Evidence-Based Treatment Algorithm
First-Line Pharmacotherapy
Atypical antipsychotics are the primary pharmacological intervention:
Risperidone demonstrates the strongest evidence with a 69% positive response rate for irritability and significant improvements in hyperactivity and stereotypy 1. Dosing ranges from 0.5-3.5 mg/day, with weight-based dosing of 0.02-0.06 mg/kg/day in children 1.
Aripiprazole shows 56% positive response at 5 mg dose versus 35% placebo, with significant improvements in irritability, hyperactivity, and stereotypy subscales 1. Flexible dosing of 5-15 mg/day is effective 1.
The 2023 Lancet Psychiatry meta-analysis confirms that atypical antipsychotics probably reduce irritability with a large effect size (SMD -0.90) and may reduce self-injury with a very large effect size (SMD -1.43), though evidence quality varies 2, 3.
Critical Monitoring Requirements
Metabolic adverse effects are the primary concern:
- Weight gain, increased appetite, fatigue, drowsiness, and drooling occur frequently 1, 3
- Monitor weight, metabolic parameters, and movement disorders at baseline and regularly during treatment
- Sedation typically occurs but may be transient
Second-Line Options When First-Line Fails
ADHD-related medications may provide modest benefit:
- These medications may reduce irritability slightly (SMD -0.20), representing a small effect 3
- Consider when hyperactivity is prominent alongside aggression
- Monitor for neurological side effects including drowsiness, emotional changes, and irritability 3
Propranolol shows emerging evidence for refractory cases:
- A 2024 pilot study demonstrated 50% symptom reduction on CGI-I and 37% reduction on ABC Irritability subscale at high doses (up to 200 mg three times daily) 4
- Large effect sizes (r = -0.74 for CGI-I) suggest meaningful clinical benefit 4
- Cardiac monitoring is essential but the 2024 study showed good safety profile with blood pressure averaging 109/72 on treatment 4
- Reserve for severe, chronic aggression refractory to standard treatments 5
Treatment-Resistant Cases
For severe, treatment-resistant irritability:
- Clozapine may be considered in tertiary care settings, with 8 of 13 patients (62%) showing treatment response in a 2026 case series 6
- Requires specialized monitoring for neutropenia and other serious adverse effects 6
- Most common side effects include sialorrhea, sedation, and increased appetite 6
Critical Practice Points
Medication should be combined with behavioral interventions - the evidence shows combining medication with parent training is moderately more efficacious than medication alone for decreasing serious behavioral disturbance 1.
Non-pharmacological interventions are emphasized first - the 2023 Lancet Psychiatry guideline strongly encourages clinicians to prioritize behavioral interventions, noting that medication is sometimes used inappropriately as the primary response and may lack efficacy due to significant side effects and poorer long-term outcomes 2.
Periodic reassessment is mandatory - determine if ongoing treatment remains necessary, as metabolic effects are often underemphasized 7. The goal is to facilitate the child's adjustment and engagement with educational interventions, not just symptom suppression 1.
Medications With Insufficient Evidence
Antidepressants show no clear evidence of effect on irritability (SMD -0.06) 3. Neurohormones may have minimal to no effect on irritability (SMD -0.18) with very uncertain evidence 3. These should not be used as primary agents for aggression in autism.